1. Home
  2. Labeler Index
  3. Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
  4. 10337-815
  5. NDC Package Code: 10337-815-06 Adoxa

NDC Package 10337-815-06 Adoxa

View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
10337-815-06
Package Description:
60 CAPSULE in 1 BOTTLE
Product Code:
10337-815
Proprietary Name:
Adoxa
Usage Information:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Doxycycline is indicated for the treatment of the following infections:  Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.   Respiratory tract infections caused by Mycoplasma pneumoniae.   Lymphogranuloma venereum caused by Chlamydia trachomatis.   Psittacosis (ornithosis) caused by Chlamydia psittaci.   Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.   Inclusion conjunctivitis caused by Chlamydia trachomatis.   Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis.   Nongonococcal urethritis caused by Ureaplasma urealyticum.   Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:   Chancroid caused by Haemophilus ducreyi.   Plague due to Yersinia pestis (formerly Pasteurella pestis).   Tularemia due to Francisella tularensis (formerly Pasteurella tularensis).   Cholera caused by Vibrio cholerae (formerly Vibrio comma).   Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus).   Brucellosis due to Brucella species (in conjunction with streptomycin).   Bartonellosis due to Bartonella bacilliformis.   Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:  Escherichia coli  Enterobacter aerogenes (formerly Aerobacter aerogenes)   Shigella species  Acinetobacter species (formerly Mima species and Herellea species)   Respiratory tract infections caused by Haemophilus influenzae.   Respiratory tract and urinary infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae).  Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae).   Skin and skin structure infections caused by Staphylococcus aureus.   Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections.When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:  Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.   Syphilis caused by Treponema pallidum.   Yaws caused by Treponema pertenue.   Listeriosis due to Listeria monocytogenes.   Vincent’s infection caused by Fusobacterium fusiforme.   Actinomycosis caused by Actinomyces israelii.   Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.In severe acne, doxycycline may be useful adjunctive therapy.
11-Digit NDC Billing Format:
10337081506
Billing Unit:
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
NDC to RxNorm Crosswalk:
60 EA
NDC to RxNorm Crosswalk:
  • RxCUI: 728207 - doxycycline monohydrate 150 MG Oral Capsule
  • RxCUI: 730065 - ADOXA 150 MG Oral Capsule
  • RxCUI: 730065 - doxycycline monohydrate 150 MG Oral Capsule [Adoxa]
  • RxCUI: 730065 - Adoxa 150 MG Oral Capsule
    • Labeler Name:
    Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
    Sample Package:
    No
    Start Marketing Date:
    06-01-2011
    Listing Expiration Date:
    12-31-2019
    Exclude Flag:
    I
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 10337-815-06?

    The NDC Packaged Code 10337-815-06 is assigned to a package of 60 capsule in 1 bottle of Adoxa, labeled by Pharmaderm A Division Of Fougera Pharmaceuticals Inc.. The product's dosage form is and is administered via form.This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package.

    Is NDC 10337-815 included in the NDC Directory?

    No, Adoxa with product code 10337-815 is excluded from the NDC Directory because it's listing has been INACTIVATED by FDA. The product was first marketed by Pharmaderm A Division Of Fougera Pharmaceuticals Inc. on June 01, 2011 and its listing in the NDC Directory is set to expire on December 31, 2019 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 10337-815-06?

    The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units. The calculated billable units for this package is 60.

    What is the 11-digit format for NDC 10337-815-06?

    The 11-digit format is 10337081506. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-210337-815-065-4-210337-0815-06